Article Commentary: ImPortance of IP-10 in Hepatitis B

Schweitzer A. , Horn J. , Mikolajczyk R.T. , Krause G. , Ott J.J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015; 386: 1546–1555.

GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 117–171.

Dandri M. , Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut 2012; 61 Suppl 1: i6–i17.

European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167–185.

Chan H.L.-Y , Thompson A. , Martinot-Peignoux M. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol 2011; 55: 1121–1131.

Limothai U. , Chuaypen N. , Khlaiphuengsin A. Association of interferon-gamma inducible protein 10 polymorphism with treatment response to pegylated interferon in HBeAg-positive chronic hepatitis B. Antivir Ther 2015; doi: 10.3851/IMP2992.

Liu M. , Guo S. , Hibbert J.M. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev 2011; 22: 121–130.

Narumi S. , Tominaga Y. , Tamaru M. , Shimai S. , Okumura H. , Nishioji K. Expression of IFN-inducible protein-10 in chronic hepatitis. J Immunol 1997; 158: 5536–5544.

Xia Y. , Stadler D. , Lucifora J. Interferon-γ and tumor necrosis factor-α produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis. Gastroenterology 2016; 150: 194–205.

Sonneveld M.J. , Arends P. , Boonstra A. , Hansen B.E. , Janssen H.L.A. Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B. J Hepatol 2013; 58: 898–903.

Jaroszewicz J. , Ho H. , Markova A. Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antivir Ther 2011; 16: 915–924.

Papatheodoridis G. , Goulis J. , Manolakopoulos S. Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy. J Hepatol 2014; 60: 62–68.

Papatheodoridis G. , Triantos C. , Hadziyannis E. Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate. J Viral Hepat 2015; 22: 1079–1087.

Deng G. , Zhou G. , Zhang R. Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers. Gastroenterology 2008; 134: 716–726.

Xu Z. , Liu Y. , Liu L. Association of interferon-gamma induced protein 10 promoter polymorphisms with the disease progression of hepatitis B virus infection in Chinese Han population. PLoS ONE 2013; 8: e72799.

Romero A.I. , Lagging M. , Westin J. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006; 194: 895–903.

Sarasin-Filipowicz M. , Oakeley E.J. , Duong F.H.T. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008; 105: 7034–7039.

Beinhardt S. , Aberle J.H. , Strasser M. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology 2012; 142: 78–85.e2.

Lagging M. , Askarieh G. , Negro F. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS ONE 2011; 6: e17232.

Wiegand S.B. , Jaroszewicz J. , Potthoff A. Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients. Clin Microbiol Infect 2015; 21: 710.e1–9.

Collins J.M. , Raphael K.L. , Terry C. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis 2015; 61: 1304–1306.

Riva A. , Laird M. , Casrouge A. Truncated CXCL10 is associated with failure to achieve spontaneous clearance of acute hepatitis C infection. Hepatology 2014; 60: 487–496.